HELSINKI, FINLAND (August 05, 2020) – MEGIN is pleased to announce the sale of our Internal Helium Recycler (IHR) to Swinburne University of Technology. Based in Melbourne Australia, Swinburne is a world-class university creating social and economic impacts through science, technology and innovation. Swinburne has an international reputation for quality research that connects science and technology with business and the community, which is well documented with their magnetoencephalography (MEG) research. This purchase was co-funded by the National Imaging Facility (NIF).
Swinburne Neuroimaging first adopted MEGIN’s magnetoencephalography (MEG) technology in 2011, which made it unique in Australia and New Zealand as the only single-site neuroimaging facility that offers both MEG and magnetic resonance imaging (MRI), an honour which they continue to hold.
MEGIN’s IHR technology brings zero helium boil-off technology to TRIUX™ MEG systems to reduce this helium consumption and spare the environment.
With the purchase of MEGIN’s IHR technology, Swinburne will completely eliminate the weekly refill by circulating their TRIUX’s helium in a closed cycle. It remains passive during a scan and doesn’t create any vibrations or acoustic noise that could impact data quality, resulting in a significant reduction in yearly operational costs, improved operational efficiency, and the highest quality scans.
Dr. Rachel Oliver (Batty), Swinburne’s Neuroimaging Operations Manager, who worked closely with the MEGIN Customer Care Team said; ”The MEGIN team have been outstanding. They have provided some of the best customer service and support that I’ve experienced, first through Swinburne’s ongoing MEG maintenance and now with the new purchase of MEGIN’s IHR.”
“We’re happy our technology continues to be a part of Swinburne’s state-of-the art neuroimaging facility supporting their cutting-edge research into the brain, and are very pleased to continue our long standing relationship.” John Fulford, Managing Director, MEGIN.
MEGIN, a Croton Healthcare company, is a neuroscience technology company based in Helsinki, Finland. The company is focused on developing innovative solutions for functional brain imaging for the presurgical evaluation of epilepsy, brain tumours or other lesions of the brain. For over 30 years, MEGIN has been the global leader in magnetoencephalography (MEG) technology, and launched in 2018 the fourth-generation MEG system, TRIUX™ neo. The TRIUX neo provides a non-invasive, real time view of patient specific neural activity with millimeter accuracy and millisecond resolution and provides the most precise information currently available on the market today.